CER Policy Does Not Equate To Head-To-Head Trials, UBC's Luce Says
Executive Summary
While there are many fears that comparative effectiveness research will be used to pick winners and losers when products are pitted against one another, United BioSource Corp.'s Bryan Luce does not see head-to-head trials becoming the primary focus of CER activity in the U.S., at least on the federal level
You may also be interested in...
Observational Study Guidance Needed For CER – Vanderbilt’s Harrell
With members of the Patient-Centered Outcomes Research Institute’s Methodology Committee expected to be named by early in 2011, one area where they could start to improve comparative effectiveness research is in providing solid guidance for conducting observational studies.
Observational Study Guidance Needed For CER – Vanderbilt’s Harrell
With members of the Patient-Centered Outcomes Research Institute’s Methodology Committee expected to be named by early in 2011, one area where they could start to improve comparative effectiveness research is in providing solid guidance for conducting observational studies.
BIO Taps Big Pharma Execs for Federal Comparative Effectiveness Research Board Nominations
Four of BIO's six nominations are also PhRMA's nominations for the Patient-Centered Outcomes Research Institute board of governors.